NCT04401124 is a clinical trial of no intervention in Gastric Cancer, sponsored by Beijing Friendship Hospital.

Who is sponsoring NCT04401124?

NCT04401124 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT04401124?

Interventions in NCT04401124: no intervention.

What condition does NCT04401124 study?

NCT04401124 studies Gastric Cancer, Colorectal Cancer, Gastrointestinal Disease.

Is NCT04401124 still recruiting?

NCT04401124 is currently status unknown. Last updated 27 May 2020.

Last reviewed 2020-05-27 · How we verify

NCT04401124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Status of Management of Surgery in Beijing During COVID-19

Status unknown Last updated 27 May 2020

What this trial tests

trial testing no intervention in Gastric Cancer in 500 participants. Status unknown.

Timeline

25 May 2020

Primary endpoint
31 May 2020

7 June 2020

Quick facts

Lead sponsor	Beijing Friendship Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	25 May 2020
Primary completion	31 May 2020
Estimated completion	7 June 2020

Drugs / interventions tested

no intervention

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →
Gastrointestinal Disease — all drugs for Gastrointestinal Disease →

Sponsor

Beijing Friendship Hospital

Who can join

Eligibility, any sex, with Gastric Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-centered, retrospective, observational study aimed at observing the current status of the management of gastrointestinal surgery during the COVID-19 pandemic, particularly the changes on surgery protocols and other key aspects of surgical workflow, so as to share experience with colleagues both domestic and abroad.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04401124 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 27 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing